— ] Shares Argos Therapeutics, Inc. Common Stock PURCHASE AGREEMENTPurchase Agreement • January 21st, 2014 • Argos Therapeutics Inc • Pharmaceutical preparations • New York
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. LICENSE AGREEMENT by and between ARGOS THERAPEUTICS, INC. and GREEN CROSS CORP.License Agreement • January 21st, 2014 • Argos Therapeutics Inc • Pharmaceutical preparations • New York
THIS LICENSE AGREEMENT (the “Agreement”), effective as of July 31, 2013 (the “Effective Date”), is by and between Argos Therapeutics, Inc., a corporation organized and existing under the laws of Delaware (“Argos”) and Green Cross Corp., a corporation organized and existing under the laws of Republic of Korea (“Green Cross”).
ARGOS THERAPEUTICS, INC. Nonstatutory Stock Option Agreement Granted Under 2014 Stock Incentive PlanStock Option Agreement • January 21st, 2014 • Argos Therapeutics Inc • Pharmaceutical preparations
ARGOS THERAPEUTICS, INC. Incentive Stock Option Agreement Granted Under 2014 Stock Incentive PlanArgos Therapeutics Inc • January 21st, 2014 • Pharmaceutical preparations
Acknowledgement and AgreementAcknowledgement and Agreement • January 21st, 2014 • Argos Therapeutics Inc • Pharmaceutical preparations • Delaware
This Acknowledgement and Agreement is dated as of November 4, 2013 (this “Agreement”) by and among Argos Therapeutics, Inc., a Delaware corporation with its principal offices located at 4233 Technology Drive, Durham, North Carolina 27704, (the “Company”) and Pharmstandard International S.A., a company organized under the laws of Luxembourg with its headquarters at Luxembourg 65, Boulevard Grande Duchesse Charlotte, L-1331 Luxembourg, Grand-Duchy of Luxembourg (the “Lead Investor”).
